The TNF receptor superfamily: Role in immune inflammation and bone formation

Immunologic Research

Volumn 27, Issue 2-3, 2003, Pages 287-294

  Cheng, Xin ^a   Kinosaki, Masa ^a   Murali, Ramachandran ^a   Greene, Mark I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Osteoclastogenesis; Peptidomimetics; RANK RANKL TNF TNFR superfamily molecules

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

BONE REMODELING; CELL ACTIVITY; CRYSTAL STRUCTURE; DENDRITIC CELL; DEVELOPMENTAL STAGE; DRUG EFFECT; IN VITRO STUDY; LIGAND BINDING; MAMMAL; MOLECULAR DYNAMICS; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

CARRIER PROTEINS; GLYCOPROTEINS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0141680167     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:27:2-3:287     Document Type: Review

References (58)

1. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959-962.
2. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998;281:1305-1308.
3. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
4. Horowitz MC, Xi Y, Wilson K, Kacena MA: Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12:9-18.
5. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
6. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, et al.: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-142.
7. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
9. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, et al.: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-2080.
10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
11. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545.
12. Hofbauer LC, Neubauer A, Heufelder aE: Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001;92:460-470.
13. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y: Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276:563-568.
14. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al.: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-286.
15. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000;289:1504-1508.
16. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
17. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
18. Kong YY, Boyle WJ, Penninger JM: Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 1999;77:188-193.
19. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, et al.: TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000;191:495-502.
20. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al.: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103:41-50.
21. Ikeda T, Kasai M, Utsuyama M, Hirokawa K: Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001;142:1419-1426.
22. Miyamoto A, Kunisada T, Hemmi H, Yamane T, Yasuda H, Miyake K, et al.: Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochem Biophys Res Commun 1998;242:703-709.
23. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, et al.: Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998;250:229-234.
24. Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, et al.: Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 1998;251:796-801.
25. Emery JG, Mcdonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al.: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14,363-14,367.
26. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, et al.: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999;190:1741-1754.
27. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC: The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 1998;273:34,120-34,127.
28. Lee ZH, Kwack K, Kim KK, Lee SH, Kim HH: Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. Mol Pharmacol 2000;58:1536-1545.
29. Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-227.
30. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, et al.: TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999;4:1041-1049.
31. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al.: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-605.
32. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, et al.: Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998;273:27,091-27,096.
33. Theill LE, Boyle WJ, Penninger JM: RANK-L AND RANK: T Cells, Bone Loss, and Mammalian Evolution. Annu Rev Immunol 2002;20:795-823.
34. Murali R, Greene MI: Structure-based design of immunologically active therapeutic peptides. Immunol Res 1998;17:163-169.
35. Lader CS, Flanagan aM: Prostaglandin E2, interleukin 1 alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998;139:3157-3164.
36. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al.: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J 1991;10:4025-4031.
37. Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O: Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 2001;28:474-483.
38. Tartaglia LA, Goeddel DV: Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J Biol Chem 1992;267:4304-4307.
39. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z: Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001;83:70-83.
40. Tartaglia LA, Rothe M, Hu YF, Goeddel DV: Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 1993;73:213-216.
41. Lee SE, Chung WJ, Kwak HB, Chung CH, Kwack KB, Lee ZH, et al.: Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001;276:49,343-49,349.
42. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000;275:31,155-31,161.
43. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, et al.: The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002;30:71-77.
44. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ: TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002;143:1108-1118.
45. Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-346.
46. Keystone EC: Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:427-443.
47. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, et al.: Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-792.
48. Morinaga T: Involvement of osteoclast differentiation factor (ODF) in osteoclast formation and immunity. Ensho to Men'eki. 2000;8:384-393.
49. Jimi E: Role of NF-.kappa.B/Rel transcription factors for the differentiation and function of osteoclasts. Bone (Osaka) 1998;12:91-98.
50. Kieber-Emmons T, Murali R, Greene MI: Therapeutic peptides and peptidomimetics. Curr Opin Biotechnol 1997;8:435-441.
51. Zhang X, Piatier-Tonneau D, Auffray C, Murali R, Mahapatra A, Zhang F, et al.: Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nat Biotechnol 1996;14:472-475.
52. Park B-W, Zhang H-T, Wu C, Berezov A, Zhang X, Dua R, et al.: Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 2000;18:194-198.
53. Berezov A, Zhang H-T, Greene MI, Murali R: Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function Analysis. J Med Chem 2001;44:2565-2574.
54. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH: Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 2001;108:971-979.
55. Banner DW, D'arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, et al.: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993;73:431-445.
56. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, et al.: Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563-571.
57. Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, et al.: Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem 2000;275:31,171-31,177.
58. Takasaki W, Kajino Y, Kajino K, Murali R, Greene MI: Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat Biotechnol 1997;15:1266-1270.